In this study, the authors discovered that sorafenib’s anti-tumor effects were increased in a mouse model of HCC by targeting the IL-6/JAK2/STAT3 signaling pathway with an IL-6 neutralizing antibody, implying that IL-6 may contribute to HCC patients’ resistance to sorafenib therapy. The gene discussed is STAT3; the disease is hepatocellular carcinoma.